N Roos

Summary

Country: Germany

Publications

  1. doi request reprint Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group
    Thomas Buchner
    University of Munster, Department of Hematology Oncology, Munster, Germany
    J Clin Oncol 27:61-9. 2009
  2. doi request reprint Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup
    Thomas Buchner
    Department of Internal Medicine A Hematology, Oncology and Pneumology, University of Munster, Albert Schweitzer Campus 1, Geb A 1, 48129 Munster, Germany
    J Clin Oncol 30:3604-10. 2012
  3. ncbi request reprint Maintenance for acute myeloid leukemia revisited
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Albert Schweitzer Str 33, Munster, 48129, Germany
    Curr Treat Options Oncol 8:296-304. 2007
  4. ncbi request reprint Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Thomas Buchner
    Department of Medicine, Hematology Oncology, University of Muenster, Muenster, Germany
    J Clin Oncol 24:2480-9. 2006
  5. ncbi request reprint Treatment of AML in biological subgroups
    Thomas Buechner
    Department of Hematology and Oncology, University Medical Center, Muenster, Germany
    Hematology 10:281-85. 2005
  6. ncbi request reprint Treatment of older patients with AML
    Thomas Buchner
    University Hospital, Department of Medicine, Hematology and Oncology, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Crit Rev Oncol Hematol 56:247-59. 2005
  7. ncbi request reprint Cross-trial networking in AML: a step forward rather than corner cutting
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Albert Schweitzer Street 33, D 48129 Munster, Germany
    Leuk Res 28:649-50. 2004
  8. ncbi request reprint 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq
    Thomas Buchner
    University Medical Center, Department of Medicine, Hematology and Oncology, University of Muenster, Ulbert Schweitzer Str 33, D 48129 Muenster, Germany
    J Clin Oncol 21:4496-504. 2003
  9. ncbi request reprint [Therapeutic strategies in acute myeloid leukemia]
    T Buchner
    Medizinische Klinik und Poliklinik A, Universitatsklinikum Munster
    Internist (Berl) 43:1203-4, 1207-11. 2002
  10. ncbi request reprint Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Germany
    Leuk Res 26:1073-5. 2002

Collaborators

Detail Information

Publications20

  1. doi request reprint Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group
    Thomas Buchner
    University of Munster, Department of Hematology Oncology, Munster, Germany
    J Clin Oncol 27:61-9. 2009
    ..The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy...
  2. doi request reprint Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup
    Thomas Buchner
    Department of Internal Medicine A Hematology, Oncology and Pneumology, University of Munster, Albert Schweitzer Campus 1, Geb A 1, 48129 Munster, Germany
    J Clin Oncol 30:3604-10. 2012
    ....
  3. ncbi request reprint Maintenance for acute myeloid leukemia revisited
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Albert Schweitzer Str 33, Munster, 48129, Germany
    Curr Treat Options Oncol 8:296-304. 2007
    ..Either single prospective trials or crosstrial networking by a common standard arm and general upfront randomization can further assess the relative value of maintenance for AML...
  4. ncbi request reprint Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Thomas Buchner
    Department of Medicine, Hematology Oncology, University of Muenster, Muenster, Germany
    J Clin Oncol 24:2480-9. 2006
    ..Whether additional intensification can add to this effect has not yet been determined...
  5. ncbi request reprint Treatment of AML in biological subgroups
    Thomas Buechner
    Department of Hematology and Oncology, University Medical Center, Muenster, Germany
    Hematology 10:281-85. 2005
  6. ncbi request reprint Treatment of older patients with AML
    Thomas Buchner
    University Hospital, Department of Medicine, Hematology and Oncology, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Crit Rev Oncol Hematol 56:247-59. 2005
    ..This finding did not vary by age under or above 60 years. Given the actual median age in this disease being more than 60 years the adequate management of older age AML remains as the major challenge...
  7. ncbi request reprint Cross-trial networking in AML: a step forward rather than corner cutting
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Albert Schweitzer Street 33, D 48129 Munster, Germany
    Leuk Res 28:649-50. 2004
    ..Recent experiences about intent-to-treat evaluation as well as a new consensus on shared protocol standards support this project...
  8. ncbi request reprint 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq
    Thomas Buchner
    University Medical Center, Department of Medicine, Hematology and Oncology, University of Muenster, Ulbert Schweitzer Str 33, D 48129 Muenster, Germany
    J Clin Oncol 21:4496-504. 2003
    ..To examine the efficacy of prolonged maintenance chemotherapy versus intensified consolidation therapy for patients with acute myeloid leukemia (AML)...
  9. ncbi request reprint [Therapeutic strategies in acute myeloid leukemia]
    T Buchner
    Medizinische Klinik und Poliklinik A, Universitatsklinikum Munster
    Internist (Berl) 43:1203-4, 1207-11. 2002
  10. ncbi request reprint Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies
    Thomas Buchner
    Department of Medicine, Hematology and Oncology, University of Munster, Germany
    Leuk Res 26:1073-5. 2002
    ....
  11. ncbi request reprint Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
    T Buchner
    Department of Hematology Oncology, University of Munster, Germany
    Int J Hematol 72:285-9. 2000
    ....
  12. ncbi request reprint Acute myeloid leukaemia (AML): treatment of the older patient
    T Buchner
    Department of Internal Medicine, University Hospital, Albert Schweitzer Str 33, Munster, D 48129, Germany
    Best Pract Res Clin Haematol 14:139-51. 2001
    ..Given that the actual median age in this disease is more than 60 years the management of older age AML remains as the major challenge...
  13. ncbi request reprint Remission induction therapy: the more intensive the better?
    T Buchner
    Department of Medicine, Hematology Oncology, University of Munster, Germany
    Cancer Chemother Pharmacol 48:S41-4. 2001
    ..The more intensive the better" is certainly not the way to go in the management of AML and other systemic malignancies but some increase in intensity may be possible and better...
  14. ncbi request reprint Acute myeloid leukemia: treatment over 60
    Thomas Buchner
    University of Munster, Department of Medicine, Hematology and Oncology, Germany
    Rev Clin Exp Hematol 6:46-59; discussion 86-7. 2002
    ..This finding did not vary by age, under or over 60 years. As the median age in this disease is more than 60 years, the adequate management of AML in older patients remains the major challenge...
  15. ncbi request reprint Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators
    T Buchner
    Department of Medicine, Hematology Oncology, University of Munster, Albert Schweitzer Strasse 33, Germany
    Eur J Clin Microbiol Infect Dis 21:337-52. 2002
    ..The general consensus of the group is that antifungal agents should be administered at sufficient dosages, rather early, and often empirically...
  16. ncbi request reprint Pulmonary nodules: experimental and clinical studies at low-dose CT
    S Diederich
    Institute of Clinical Radiology, University of Munster, Germany
    Radiology 213:289-98. 1999
    ..To compare the number of pulmonary nodules detected at helical low- and standard-dose computed tomography (CT) and to investigate the diagnostic value of low-dose CT with a radiation exposure equivalent to that used at chest radiography...
  17. ncbi request reprint Coexistence of non-Hodgkin's lymphoma and non-small cell lung carcinoma: diagnosis and treatment
    M Rothenburger
    Department of Cardiothoracic Surgery, University of Muenster, Germany
    Thorac Cardiovasc Surg 50:59-61. 2002
    ..Restaging after six months showed no evidence of a tumor relapse. This is a very rare case of the coexistence of NHL and NSCLC; we will discuss the difficulty of diagnostic and treatment of both tumor diseases...
  18. ncbi request reprint Efficacy and safety of thalidomide in patients with acute myeloid leukemia
    Martin B Steins
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, D 48129 Muenster, Germany
    Blood 99:834-9. 2002
    ..In conclusion, single-agent thalidomide has antiangiogenic and antileukemic activity in AML, although a causal relationship between both effects has still to be proven...
  19. ncbi request reprint Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide
    Michael Kreuter
    Department of Medicine Hematology and Oncology, University of Muenster, Muenster, Germany
    Eur J Haematol 79:392-7. 2007
    ..The role of NRP-1 in refractory or relapsed AML patients and its regulation during anti-angiogenic treatment remain to be elucidated...
  20. ncbi request reprint Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia
    Ruediger Liersch
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, D 48129 Muenster, Germany
    Leuk Res 32:954-61. 2008
    ..Although expression levels display no prognostic significance in our study, strategies targeting the VEGF-C/VEGFR-3-pathway might be a promising treatment approach...